Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14177933 | 0.90 | CYP11B2 (0.49) | KDM4EGRM1RXFP1CYP11B2 | |
| SCHEMBL13035731 | 0.89 | KDM4E (0.59) | KDM4EGPR119RXFP1TP53L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL8131031 | 0.88 | KDM4E (0.57) | KDM4EGPR119RXFP1TP53L3MBTL1 | |
| SCHEMBL13703142 | 0.85 | KDM4E (0.46) | KDM4EGPR119GRM1RXFP1TP53 | |
| SCHEMBL24928451 | 0.79 | KDM4E (0.52) | KDM4EGPR119GRM1RXFP1TP53 | |
| SCHEMBL30718898 | 0.79 | KDM4E (0.52) | KDM4EGPR119GRM1RXFP1TP53 | |
| SCHEMBL1267664 | 0.79 | KDM4E (0.49) | KDM4EGPR119GRM1RXFP1TP53 | |
| SCHEMBL18239409 | 0.79 | KDM4E (0.49) | KDM4EGPR119RXFP1 | |
| SCHEMBL27140276 | 0.79 | KDM4E (0.52) | KDM4EGPR119GRM1RXFP1TP53 | |
| SCHEMBL12988997 | 0.79 | KDM4E (0.49) | KDM4EGPR119GRM1RXFP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| WO-2007081897-A2 | FUSED TRIAZOLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KDM4E 3396/4885GPR119 77/4885GRM1 58/4885 |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | KDM4E 3697/4885GPR119 370/4885GRM1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.